益肺通络方联合化疗方案治疗耐多药肺结核近期疗效观察

Short-term Therapeutic Effect of Yifei Tongluo Decoction Combined with Chemotherapy for Multidrug-resistant Tuberculosis

目的:观察和评价益肺通络方联合化疗方案治疗耐多药肺结核的疗效。方法:将131例患者随机分为2组。治疗组79例,采用益肺通络方联合化疗方案治疗;对照组52例,采用单纯化疗方案治疗。2组疗程均为3月。结果:疗程结束时,治疗组在痰菌阴转率、肺部X线病灶吸收、空洞闭合、临床症状改善以及免疫功能改善情况均优于对照组,其中,2组痰菌培养阴转率及肺部X线病灶吸收有效率比较,差异均有显著性意义(P<0.05)。结论:采用益肺通络方联合化疗方案治疗耐多药肺结核可以促进痰菌阴转及肺部病灶吸收,近期疗效有效且安全,为耐多药肺结核患者中西医结合治疗提供新方案奠定了前期基础,具有临床推广应用前景。

Objective： To evaluate the therapeutic effect of Yifei Tongluo Decoction combined with chemotherapy for the treatment of multidrug-resistant tuberculosis. Methods： One hundred and thirty-one patients were randomly divided into the treatment group and the control groups. The treatment group with 79 cases was given Yifei Tongluo Decoction combined with anti-tuberculosis drugs, and the control group with 52 cases was given anti-tuberculosis drugs. The course of treatment was 3 months. Results： At the end of treatment, sputum negative conversion rate, focus absorption and cavity closure showed by lung X-ray image, the improvement of clinical symptoms and immune function in the treatment group were better than those in the control group, the differences of sputum conversion rate and focus absorption being significant（P 〈 0.05）. Conclusion： Yifei Tongluo Decoction combined with chemotherapy can improve sputum negative conversion and focus absorption, has better short-term effect and is safe for the treatment of multidrug-resistant tuberculosis, which will lay the foundation for integrated Chinese and western medicine therapy for multidrug-resistant tuberculosis, and is expected to having wide clinical application.